Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 2.11 [1.41, 3.15]
3 studies · 971 participants
Low

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.64 [1.22, 2.21]
5 studies · 170 participants
Low

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 15.62 [0.94, 260.49]
1 study · 69 participants
Low